Sanofi buys Freeslate's Biologics Formulation System for vaccine research

Freeslate, Inc., a Sunnyvale, California-based provider of high throughput research solutions, announced on Wednesday that Sanofi Pasteur bought Freeslate's Biologics Formulation System to accelerate vaccine research.

Freeslate's Biologics Formulation System automates the sample preparation, sample stressing and formulation analysis to enable the development of robust, stable formulations quickly and with reduced consumption of resources. The system is based on Freeslate's Core Module III automation platform.

The Biologics Formulation System combines controlled heating/cooling/mixing and liquid dispense with automated measurements of particle counting, viscosity and pH. Freeslate said the system maximizes research and development productivity by providing intuitive experiment design and the data integration of third-party analytics like high pressure liquid chromatography and dynamic light scatter.

"We are excited to be selected by a global leader in vaccines and are pleased they recognize the value our tools bring to the advancement of formulation development," John Senaldi, the president and CEO of Freeslate, said. "As demonstrated by the adoption of our systems in Europe and across the globe, combinatorial approaches to vaccine formulation development can significantly accelerate productivity."

Sanofi Pasteur is the vaccines division of French pharmaceutical company Sanofi.

Freeslate is a privately-held company with products that allow customers to more effectively manage capacity by assessing and performing formulations, minimizing later stage reformulations and managing data to improve decision making.